Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Blood Test Detects All Known Inherited Heart Conditions Genes

By LabMedica International staff writers
Posted on 28 Feb 2016
A rapid, simple blood test has been developed that accurately can detect all known genes associated with inherited heart conditions which are characterized by marked genetic and allelic heterogeneity and require extensive sequencing for genetic characterization. More...


Inherited heart conditions are caused by gene mutations that have been passed down from relatives. If a mother possesses one of these faulty genes, there is a 50% chance that they will pass the mutation on to their child. These heart conditions include aortic valve disease, structural heart disease, long and short QT syndrome, Noonan syndrome, familial atrial fibrillation and most cardiomyopathies.

Scientists at the Imperial College London (UK) working with their colleagues analyzed the blood samples of 348 participants from the National Heart Center (Singapore). Genomic DNA was extracted from blood using Prepito DNA Blood 600 kit (Perkin Elmer, Waltham, MA, USA) for targeted sequencing; EZ1 DSP DNA blood 48 kit (Qiagen, Venlo, Netherlands) for whole exome sequencing, (WES) or the Qiagen QIAsymphony DNA kit for whole genome sequencing (WGS).

Quality and quantity of extracted DNA were assessed by an ultraviolet-visible spectrophotometer. For targeted sequencing pooled libraries were prepared using the inherited cardiac conditions (ICC) panel and were sequenced on the MiSeq (108 samples) or NextSeq 500 (144samples) benchtop sequencers (Illumina; San Diego, CA, USA) using paired-end, 150 bp reads. Pathogenic or likely pathogenic variants of 26 samples were identified using the ICC panel in a study cohort of 35 samples was subjected to Sanger sequencing.

The new test used next-generation sequencing to simultaneously identify 174 genes known to increase the risk of 17 inherited heart conditions. The team found that the test was able to quickly identify all gene mutations in the blood samples that were associated with the 17 inherited heart conditions with up to 100% accuracy. The assay has better performance, shorter turnaround times, lesser informatics requirements and lower sequencing costs as compared to the WES, deep WES, and WGS. The assay is called the TruSight Cardio Sequencing Kit.

James S. Ware, MD, PhD, a cardiologist and coauthor of the study said, “Without a genetic test, we often have to keep the whole family under regular surveillance for many years, because some of these conditions may not develop until later in life. This is hugely costly for both the families and the health system. By contrast, when a genetic test reveals the precise genetic abnormality causing the condition in one member of the family, it becomes simple to test other family members. Those who do not carry the faulty gene copy can be reassured and spared countless hospital visits. This new comprehensive test is increasing the number of families who benefit from genetic testing.” The study was published on February 17, 2016, in the Journal of Cardiovascular Translational Research.

Related Links:

Imperial College London 
Singapore National Heart Center
Illumina 



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.